Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single‐arm, exploratory phase II trial

Abstract Background The poor overall survival of osteosarcoma (OS) underscores the need to explore new therapeutic avenues. Tumor necrosis rate (TNR) after neoadjuvant chemotherapy predicts prognosis. Aims The study was to investigate safety and activity of neoadjuvant chemotherapy with camrelizumab...

Full description

Bibliographic Details
Published in:Cancer Medicine
Main Authors: Qinglian Tang, Xinke Zhang, Xiaojun Zhu, Huaiyuan Xu, Guohui Song, Jinchang Lu, Hao Wu, Chuangzhong Deng, Fei Ai, Yingchun Zhang, Jin Wang
Format: Article
Language:English
Published: Wiley 2024-09-01
Subjects:
camrelizumab
neoadjuvant therapy
osteosarcoma
programmed cell death receptor 1
Online Access:https://doi.org/10.1002/cam4.70206

Internet

https://doi.org/10.1002/cam4.70206

Similar Items